Venetoclax for CLL patients who progress after MORE THAN ONE B‐cell receptor pathway inhibitor

[Jm954]

27/11/18

This study represents the first retrospective analysis of this high‐risk patient population, who were uniformly evaluated as part of a prospective trial with an effective therapy.

With higher ORR and longer PFS for patients who only received 1 vs. >1 prior BCRi, these data support the earlier use of venetoclax in the treatment paradigm to optimize response, though venetoclax was still active in this poor‐risk group of patients who had received >1 prior BCRi.

Given the relatively small number of patients treated with venetoclax after discontinuing multiple BCRi who had lower responses and remission durations than those treated earlier in their disease, consideration of transitioning such patients after disease control is obtained to either CAR‐T therapy trials or allogeneic SCT could be pursued if patients are eligible.

more here: onlinelibrary.wiley.com/doi...

Jackie

[Wroxham]

Thank you Jackie.

[Bell53]

Good information to have access to - thank you Jackie

[Smakwater]

I was a bit challenged with the focus having so many subsets, and having to review the hyperlinks in order to process a conclusion.

It appeared that the object was to show venetoclax providing significant ORR and MRD negative responses for patients having poor responses on other B cell inhibiting drugs?

If so, looks like venetoclax is a good salvage option.

JM

[Jm954 Administrator in reply to Smakwater]

Yep, which is good as it's pretty much all that is left after those treatments apart from SCT or CAR-T

Jackie